AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00712205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: once daily 1mcg Placebo for 28days followed by crossover treatment
Study NCT00712205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
Study NCT02263235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: administration of stable isotope-labelled leucine-
Description: - administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
Study NCT02263235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of CSF, blood, urine, saliva
Description: - administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
Study NCT01988961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: SC injections
Study NCT02757976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CRT
Description: Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
Study NCT02757976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LV endocardial CRT
Description: Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
Study NCT02930486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZipTight suture endobutton
Description: Zimmer Biomet ZipTight suture endobutton
Study NCT02930486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tricortical 3.5 mm syndesmotic screw
Description: Depuy Synthes 3.5 mm screw
Study NCT04205019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neuro-Cells
Description: Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
Study NCT03081234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
Study NCT03081234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
Study NCT03081234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant endocrine therapy
Description: Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
Study NCT03081234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Description: Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
Study NCT02721693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test
Description: Patients are subjected to an incremental exercise test to exhaustion on a treadmill
Study NCT02453776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRECISION dosing Infliximab
Description: Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
Study NCT02442674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days
Study NCT02442674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching active drug
Study NCT04710966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic debridement
Description: For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.
Study NCT04710966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic repair
Description: For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
Study NCT00860366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uric Acid
Description: 1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
Study NCT00860366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
Study NCT04275765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2:Behavioral Intervention with nudges & Facebook interaction
Description: Participants will receive nudges and be enrolled to Facebook group for self-learning.
Study NCT04275765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.
Description: Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
Study NCT02655744 — intervention group
Intervention type: RADIATION
Intervention: Standard treatment protocol with combined chemoradiation
Study NCT03311100 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression
Study NCT06171607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS
Study NCT06171607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV
Study NCT06171607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV
Study NCT01983917 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Mobile Application
Study NCT01555008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Subjects will receive LX4211 once daily for 7 days
Study NCT01555008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Description: Subjects will receive LX4211 placebo once daily for 7 days
Study NCT02375139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01
Description: complex single administration
Study NCT02375139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E+M
Description: co-administration of 2 drugs
Study NCT01234792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg Experimental nicotine gum
Description: A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
Study NCT01234792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg Nicotine Gum/
Description: A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
Study NCT01234792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg Nicotine Gum
Description: A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
Study NCT02685202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint
Description: A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
Study NCT01574482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).
Description: 1 = Intervention 1 (1 test product/day)
Study NCT01574482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
Description: 2 = Intervention 2 (1 control product/day)
Study NCT01297387 — intervention group
Intervention type: OTHER
Intervention: PTA BPG procedure,
Description: Surgery PTA or BPG Procedure, according usual local clinical practice
Study NCT00085423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: ‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
Study NCT00085423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
Study NCT00085423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
Study NCT00085423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
Study NCT01327261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa + benserazide
Description: Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
Study NCT01327261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa + benserazide
Description: Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
Study NCT03106831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pituitrin infusion
Description: To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
Study NCT03106831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
Study NCT02267824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fixed Orthodontic Appliance Treatment
Description: Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
Study NCT02735850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2
Description: L19-IL2 added to SBRT
Study NCT02735850 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Study NCT02735850 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study NCT02735850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study NCT02018783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colgate
Description: Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
Study NCT02018783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensodyne
Description: Digital application for 60 seconds.
Study NCT02018783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nano P
Description: Slow-speed handpiece with a Robson brush for 10 seconds
Study NCT04608305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100, low dose (prime)
Description: Single administration of IIBR-100 1\*10E5 pfu/ml
Study NCT04608305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 medium dose (prime)
Description: Single administration of IIBR-100 1\*10E6 pfu/ml
Study NCT03440554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body Non-Contrast MRI
Description: Whole Body Non-Contrast MRI in Prostate Cancer Patients
Study NCT02592278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: Application of fluoride varnish every 3 and 6 months.
Study NCT02592278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Twice a day brush with fluoride toothpaste.
Study NCT01653444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1119
Description: biweekly, IV infusion
Study NCT00365339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir+Ritonavir+Tenofovir
Description: Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
Study NCT00365339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
Study NCT00365339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
Study NCT00365339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
Study NCT00365339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
Study NCT00921388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varenicline and smoking cessation counseling
Description: All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
Study NCT00921388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Varenicline and smoking cessation counseling
Description: All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
Study NCT00921388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise or relaxation treatment
Description: One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
Study NCT03680534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal preparation
Description: Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
Study NCT04170088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid intradermal injections were used for treatment of melasma
Study NCT04170088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Normal Saline
Description: Normal saline used for comparision of efficacy of tranexamic acid
Study NCT03475342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Ampoules and packaging for both arms will be identical in appearance.
Study NCT03475342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ampoules and packaging for both arms will be identical in appearance.
Study NCT01979718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirrored Virtual reality
Description: Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
Study NCT01979718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirrored Virtual reality
Description: Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
Study NCT01219101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate with ethinyl esteradiol
Description: Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
Study NCT01219101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate with plasebo
Description: Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
Study NCT00498043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP14 induction regimen
Description: R-CHOP14 induction regimen
Study NCT00498043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-ACVBP14 induction regimen
Description: R-ACVBP14 induction regimen
Study NCT03082677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
Study NCT04410965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERIFLUNOMIDE
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT04118543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
Study NCT04118543 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Exercise Group
Description: Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
Study NCT00953953 — intervention group
Intervention type: DEVICE
Intervention: Phillips ultrasound system
Description: The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
Study NCT03780751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
Study NCT03780751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment
Description: MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).